Transcriptomics-inferred dynamics of SARS-CoV-2 interactions with host epithelial cells

Lukas Adam1, Megan Stanifer2,3, Fabian Springer1

  • 1Health Data Science Unit, University Hospital Heidelberg and Center for Quantitative Analysis of Molecular and Cellular Biosystems (BioQuant), University of Heidelberg, Heidelberg 69120, Germany.

Science Signaling
|September 26, 2023
PubMed

Insights

This study reveals how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disrupts host cell functions, including metabolism and antiviral responses. Targeting host cell pathways shows promise for developing new antiviral therapies against SARS-CoV-2 infection.

Area of Science:

  • Virology
  • Molecular Biology
  • Cellular Biology

Background:

  • Virus-host interactions are crucial for understanding infection dynamics and identifying therapeutic targets.
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection profoundly impacts host cell processes.

Purpose of the Study:

  • To investigate the dynamic interplay between SARS-CoV-2 replication and the host cell's transcriptional response.
  • To identify host pathways that can be targeted for antiviral therapy.

Main Methods:

  • Time-resolved RNA sequencing of SARS-CoV-2 infected Caco-2 cells.
  • Mathematical modeling of virus replication and host-virus interactions.
  • Assessment of host-targeted kinase inhibitors against viral replication.

Main Results:

  • SARS-CoV-2 infection rapidly alters host gene expression, affecting inflammatory, ribosomal, and mitochondrial pathways.
  • Viral proteins were found to inhibit the host antiviral response, with viral transcripts exceeding host translation capacity.
  • Targeting specific kinase-dependent pathways in host cells proved effective in inhibiting viral replication.

Conclusions:

  • The study delineates a temporal sequence of SARS-CoV-2 host-virus interactions.
  • Host cell pathways, particularly kinase-dependent ones, represent viable targets for developing novel antiviral strategies against SARS-CoV-2.